Could a diabetes drug shield kids' kidneys from protein damage?
NCT ID NCT07204743
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Summary
This study tests a drug called dapagliflozin (Forxiga) in 10 children aged 4-18 who have kidney disease and persistent protein in their urine despite standard treatment. The goal is to see if the drug can reduce protein leakage and protect kidney function. Participants take the drug and have their urine protein and kidney filtration rate measured before and after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SGLT 2 INHIBITORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Al Ahli hospital
Hebron, Palestine, P700, Palestinian Territories
Conditions
Explore the condition pages connected to this study.